Smith Robin L 4
4 · Matinas BioPharma Holdings, Inc. · Filed May 2, 2025
Insider Transaction Report
Form 4
Smith Robin L
Director
Transactions
- Award
Stock Option (right to Buy)
2025-04-30+11,600→ 11,600 totalExercise: $0.59Exp: 2035-04-30→ Common Stock (11,600 underlying)
Footnotes (1)
- [F1]The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. 100% of the options vest, subject to stockholder approval of the 2025 Plan, on April 30, 2026.